LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

44.66 0.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

44.19

Максимум

44.67

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+24.95% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	19M 3.2B
Предишно отваряне	44.03
Предишно затваряне	44.66

Настроения в новините

By Acuity

34%

66%

91 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.11.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 19:59 ч. UTC

Пазарно говорене

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28.11.2025 г., 19:47 ч. UTC

Пазарно говорене

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 17:48 ч. UTC

Пазарно говорене

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28.11.2025 г., 15:51 ч. UTC

Пазарно говорене

Canada Household Spending Edges Lower -- Market Talk

28.11.2025 г., 15:33 ч. UTC

Пазарно говорене

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28.11.2025 г., 15:21 ч. UTC

Пазарно говорене

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28.11.2025 г., 15:13 ч. UTC

Пазарно говорене

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28.11.2025 г., 14:51 ч. UTC

Пазарно говорене

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28.11.2025 г., 14:41 ч. UTC

Пазарно говорене

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28.11.2025 г., 14:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28.11.2025 г., 14:20 ч. UTC

Пазарно говорене

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28.11.2025 г., 14:10 ч. UTC

Пазарно говорене

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28.11.2025 г., 13:36 ч. UTC

Пазарно говорене

Canada's Economy Expands More Than Expected -- Market Talk

28.11.2025 г., 13:29 ч. UTC

Пазарно говорене

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28.11.2025 г., 13:27 ч. UTC

Пазарно говорене

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28.11.2025 г., 13:19 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

24.95% нагоре

12-месечна прогноза

Среден 55.59 USD 24.95%

Висок 65 USD

Нисък 44 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

91 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.